TRUFILL n-BCA Liquid Embolic System
Cerenovus, Inc. · Decision date Aug 22, 2025
What did the FDA decide?
FDA records P990040/S036 as a supplement to PMA P990040, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 22, 2025.
FDA approval order statement
approval for an alternative identification method for the ethiodized oil component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Aug 22, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P990040/S036
- Regulatory pathway
- PMA supplement
- Applicant
- Cerenovus, Inc.
- Product code
- KGG
- Decision code
- OK30
- Decision date
- Aug 22, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: tissue adhesive for use in embolization of brain arteriovenous malformations.
- Applicant
- Cerenovus, Inc.
- Product code
- KGG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P990040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P990040 · Original PMA
TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
P990040/S036 received
Application receipt date recorded by FDA.
P990040/S036 · FDA decision
30-Day Notice
P990040/S034 · Related supplement
TRUFILL n-BCA Liquid Embolic System (LES), TRUFILL n-BCA Liquid Embolic System Procedural Set
P990040/S038 · Related supplement
TRUFILL n-BCA Liquid Embolic System
P990040/S037 · Related supplement
TRUFILL n-BCA Liquid Embolic System
Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cerenovus, Inc. | PMA approval | Sep 25, 2000 | FDA | |
| Cerenovus, Inc. | PMA supplement | Dec 16, 2025 | FDA | |
TRUFILL n-BCA Liquid Embolic SystemP990040/S038 | Cerenovus, Inc. | PMA supplement | May 26, 2026 | FDA |
TRUFILL n-BCA Liquid Embolic SystemP990040/S037 | Cerenovus, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cerenovus, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6303 Waterford District Dr., Suite 315, Miami, FL, 33126
Sources and methodology
- Original FDA record: P990040/S036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

